Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Trial Profile

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Depatuxizumab (Primary) ; Nivolumab (Primary) ; Ramucirumab (Primary) ; Rilotumumab (Primary) ; Trastuzumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms PANGEA; PANGEA-IMBBP
  • Most Recent Events

    • 29 Apr 2019 Planned End Date changed from 1 Oct 2018 to 1 Feb 2022.
    • 29 Apr 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Feb 2020.
    • 28 Jan 2019 Results evaluating effect of ramucirumab on clinical activity of FOLFIRI as 3rd line therapy in metastatic gastric Cancer patients were published in the Investigational New Drugs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top